NRF2 promotes cell protection against oxidative stress, chemotherapy and radiotherapy, and it has been observed that cisplatin-induced ROS generation triggers intranuclear activation of NRF2 via SENP3 activity, which may be related to diminished cancer cell responses to chemotherapy [120]. This evidence concerns the gene SENP3 and cancer.